UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 21, 2016
Cerecor Inc.
(Exact name of Registrant as Specified in Its Charter)
| | | | |
Delaware | | 001-37590 | | 45-0705648 |
(State or Other Jurisdiction
of Incorporation) | | (Commission
File Number) | | (IRS Employer Identification No.) |
| | |
400 E. Pratt Street Suite 606 Baltimore, Maryland | | 21202 |
(Address of Principal Executive Offices) | | (Zip Code) |
Registrant’s Telephone Number, Including Area Code: (410) 522-8707
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01.Regulation FD Disclosure.
On September 21, 2016, Cerecor Inc. (the “Company”) issued a press release, further described in Item 8.01 below, in connection with the completion of patient enrollment in its Phase 2 clinical trial with CERC-301 as an oral, adjunctive treatment of major depressive disorder. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 8.01.Other Events.
Completion of Patient Enrollment of Phase 2 Clinical Trial with CERC-501 for Smoking Cessation
On September 21, 2016, the Company announced the completion of patient enrollment in its Phase 2 clinical trial with CERC-301, Clin301-203. The Company expects to report top-line data from this trial in November 2016. The primary objective of the study is to evaluate the antidepressant effect of CERC-301 compared to placebo.
Item 9.01.Financial Statements and Exhibits.
| | |
Exhibit No. | | Description |
| | |
99.1 | | Press Release, dated September 21, 2016, entitled “Cerecor Announces Completion of Enrollment in Phase 2 Clinical Trial with CERC-301 as an Oral, Adjunctive Treatment of Major Depressive Disorder.” |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | | |
| | Cerecor Inc. |
| | | |
| | By: | /s/ Mariam Morris |
| | | Mariam Morris |
| | | Chief Financial Officer |
Date: September 21, 2016
EXHIBIT INDEX
| | |
Exhibit No. | | Description |
| | |
99.1 | | Press Release, dated September 21, 2016, entitled “Cerecor Announces Completion of Enrollment in Phase 2 Clinical Trial with CERC-301 as an Oral, Adjunctive Treatment of Major Depressive Disorder.” |
